Regen Biopharma Inc. (OTCMKTS:RGBP) has huge potential and risk as well. On April 8, 2021, the stock soared 571%, and although the massive rally isn’t surprising for a penny stock, it is vital to understand the trigger and whether it has long-term potential.
The company focuses on the immunotherapy and immunology sector, and it plans to advance proprietary technologies via preclinical and Phase I & II clinical studies. Currently, Regen is advancing small molecule therapies for autoimmune disorders and cancer treatment.
The news that triggered that stock surge was the announcement that the company had signed a licensing agreement for its treatment for pancreatic cancer. The company entered a deal with Oncology Pharma pursuant to which Oncology Pharma will receive access to Regen’s IP related to the mRNA used in creating a therapy for pancreatic cancer treatment.As per the agreement, Regen will receive a non-refundable fee of $55,000, 5% royalties in net sales, and 10% of all consideration the licensee will receive from sublicensees. RGBP is worth keeping an eye on.
On Tuesday, RGBP stock rose 11.96% at $0.0234 with more than 65.30 million shares, compared to its average volume of 116.44 million shares. The stock has moved within a range of $0.0205 – 0.0238 after opening the trade at $0.0223.